Pemigatinib: First Approval

This article summarizes the milestones in the development of pemigatinib leading to this first approval for the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma and a FGFR 2 fusion or other rearrangement, as detected by a US FDA-approved test.

http://link.springer.com/10.1007/s40265-020-01330-y

Source: Drugs - May 28, 2020 Category: Drugs & Pharmacology Source Type: research